PHI with Atrophic ulcer of the lower extremity
How does this condition affect your private health insurance?
An atrophic ulcer of the lower extremity is a chronic, non-healing open sore on the leg or foot, stemming from poor tissue nourishment due to underlying vascular insufficiency. Unlike acute wounds, these ulcers struggle to heal because of inadequate blood supply—arterial, venous, or both—leading to thin, fragile skin and deep tissue damage. They are often painful, highly prone to infection, and significantly impair mobility and quality of life. Without proper diagnosis and management of the root cause, such as peripheral artery disease or chronic venous insufficiency, these ulcers can persist for months or years, frequently recurring. Treatment targets circulation improvement, meticulous wound care, and complication prevention.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several weeks to months, often years if underlying cause is not addressed
Duration of Illness (Lifetime)
Chronic, recurrent disease, often lifelong management required
Cost of Treatment (Initial)
Moderate to high (e.g., $1,000 - $10,000+ for initial diagnostics, wound care, medication, specialist visits)
Cost of Treatment (Lifetime)
High to very high (e.g., $10,000 - $100,000+ due to chronic management, recurrences, complications, potential surgeries or amputations)
Mortality Rate
Low directly from the ulcer itself, but 1-5% due to severe infection (sepsis) or complications of underlying disease (e.g., cardiovascular events in PAD patients)
Risk of Secondary Damages
Very high (>70%): chronic pain, recurrent infection, reduced mobility, limb amputation, psychological distress, decreased quality of life
Probability of Full Recovery
Moderate (30-60% for full closure, but recurrence is common). Complete recovery without *any* consequences is lower, especially with underlying chronic conditions.
Underlying Disease Risk
Very high (>90%): peripheral artery disease, chronic venous insufficiency, diabetes mellitus, neuropathy, vasculitis, pressure-induced ischemia, lymphedema